Mesoporous black TiO2 phase junction@Ni nanosheets: A highly integrated photocatalyst system

Wei Li,Lin OuYang,Yuxia Tang,Zhaogang Teng,Xiaodan Su,Jiang Wu

DOI: https://doi.org/10.1016/j.jtice.2020.09.009

IF: 5.477

2020-09-01

Journal of the Taiwan Institute of Chemical Engineers

Abstract:A highly integrated photocatalyst system is constructed.Mesoporous black TiO₂ phase nanosheets are prepared.The integrated photocatalyst shows good visible light utilization, rapid charge separation, and efficient photocatalytic H₂ evolution.Ni nanosheets enables easy magnetic recovery and reuse of the powered photocatalysts.Solar fuels production by using TiO₂ nanomaterials has attracted much attention to overcome the energy and environmental crisis. However, it is a big challenge to utilize the visible light, promote charge separation and surface reaction, and efficiently recover nanosized TiO₂ photocatalysts without secondary contamination. Here, Ni nanosheets as the non-noble metal co-catalysts are coated on the surface of mesoporous black TiO₂ phase junction microspheres (Ni/b–TiO₂) for highly efficient H₂ evolution. The black TiO₂ phase junction core can efficiently harvest the visible light and greatly facilitate the charge transfer. The Ni nanosheet shell can not only serve as a highly efficient collaborative co-catalyst to promote the separation and transfer of photogenerated charge carriers, but also enhance the visible light absorption and improve the utilization ratio of sunlight. The obtained Ni/b–TiO₂ exhibits a high hydrogen evolution rate of 166.2 µmol h^-1 g^-1 under simulated sunlight, which is much higher than that of pristine mesoporous black TiO₂ microspheres (80.5 μmol h^-1 g^-1). More importantly, the obtained photocatalysts can be easily separated through magnetic separation. Such a structure design may provide new insights for fabricating low-cost bifunctional photocatalysts with high-performance.

engineering, chemical

What problem does this paper attempt to address?

The main issue this paper attempts to address is the safety, tolerability, acceptability, and immunogenicity of delivering the influenza vaccine to human skin using a novel high-density microprojection array patch (Nanopatch™). Specifically, the study aims to evaluate the following aspects:

1. **Safety**: Assess the safety of using Nanopatch™ in human volunteers, including local reactions and systemic adverse events.
2. **Tolerability**: Evaluate the skin reactions at the application site of Nanopatch™ and the users' tolerance to this new delivery method.
3. **Acceptability**: Understand participants' acceptance of Nanopatch™ through questionnaires and interviews, and their preference compared to traditional needle injections.
4. **Immunogenicity**: Assess whether the influenza vaccine delivered by Nanopatch™ can effectively induce an immune response, and whether it has similar or better effects compared to traditional intramuscular injections.

### Study Background:
The most commonly used method for vaccine administration currently is using needles and syringes (N&S), but this method has some drawbacks, such as requiring professional healthcare personnel, fear of needles, risk of needlestick injuries, and the need to reconstitute lyophilized vaccines. Nanopatch™ is a novel microarray skin patch with a high-density microprojection structure that can dry-coat vaccines, aiming to overcome these drawbacks.

### Study Methods:
- Healthy volunteers were randomly assigned to one of six groups, receiving different types of vaccines or placebo treatments.
- Primary evaluation metrics included hemagglutination inhibition (HAI) and microneutralization (MN) antibody responses measured on days 0, 7, and 21.
- Secondary evaluation metrics included local skin reactions, pain scores, and participants' acceptance of Nanopatch™.

### Study Results:
- **Safety**: Nanopatch™ administration was generally safe, with all adverse events being mild or moderate.
- **Tolerability**: Most local skin reactions were mild or moderate and gradually subsided over time.
- **Acceptability**: 55% of participants preferred Nanopatch™, while only 24% preferred traditional needle injections.
- **Immunogenicity**: The Nanopatch™ group showed significantly higher HAI and MN antibody titers on days 7 and 21 compared to baseline, with immune responses similar to the intramuscular injection group.

### Conclusion:
Nanopatch™ demonstrated good safety, tolerability, and acceptability in its first human trial and effectively induced an immune response comparable to intramuscular injections. This provides strong support for further research and potential clinical applications in the future.